Literature DB >> 8352181

Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide and plasminogen activator inhibitor-1.

M Negri1, I Sheiban, P L Arigliano, S Tonni, G Montresor, S Carlini, F Manzato.   

Abstract

Plasma insulin, C-peptide and plasminogen activator inhibitor-1 (PAI-1) levels were measured in 64 men with coronary artery disease (CAD) documented by angiography. Coronary arteriograms were analyzed, and the severity and diffusion of coronary lesions were quantified by score systems. C-peptide and PAI-1 levels in patients with CAD were significantly higher than in 30 control subjects. Insulin, C-peptide and PAI-1 showed a highly significant correlation with the severity scores for coronary lesions (C-peptide more than insulin), but only a weak correlation with diffusion scores. Highly significant correlations were found between insulin and PAI-1, and even greater ones between C-peptide and PAI-1. It has been proposed that hyperinsulinemia may be involved in the etiology of atherosclerotic cardiovascular disease by dysregulating lipoprotein metabolism and blood pressure. These findings support that hypothesis and suggest that insulin secretion may be an index of the severity of CAD. Because a direct effect of insulin on the cells that synthesize PAI-1 has been shown, the present data further indicate that the effect of insulin on fibrinolysis may be another way by which hyperinsulinemia accelerates atherogenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8352181     DOI: 10.1016/0002-9149(93)91129-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model.

Authors:  M R Gyetko; G H Chen; R A McDonald; R Goodman; G B Huffnagle; C C Wilkinson; J A Fuller; G B Toews
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

2.  Fibrinolytic variables in postmenopausal women with unstable coronary artery disease.

Authors:  N E Nielsen; E Logander; E Swahn
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

3.  Effects of the shape of coronary arteries on the presence, extent, and severity of their disease.

Authors:  Recep Demirbag; Remzi Yilmaz
Journal:  Heart Vessels       Date:  2005-09       Impact factor: 2.037

4.  The association of QT dispersion and QT dispersion ratio with extent and severity of coronary artery disease.

Authors:  Remzi Yilmaz; Recep Demirbag; Mustafa Gur
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-01       Impact factor: 1.468

5.  The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy.

Authors:  Gultekin F Hobikoglu; Tugrul Norgaz; Huseyin Aksu; Orhan Ozer; Mehmet Erturk; Evren Destegul; Umit Akyuz; Sennur Unal Dai; Ahmet Narin
Journal:  Can J Cardiol       Date:  2007-03-01       Impact factor: 5.223

6.  Predictor of poor coronary collaterals in chronic kidney disease population with significant coronary artery disease.

Authors:  Po-Chao Hsu; Suh-Hang Juo; Ho-Ming Su; Szu-Chia Chen; Wei-chung Tsai; Wen-Ter Lai; Sheng-Hsiung Sheu; Tsung-Hsien Lin
Journal:  BMC Nephrol       Date:  2012-08-30       Impact factor: 2.388

7.  Influence of high-density lipoprotein cholesterol on coronary collateral formation in a population with significant coronary artery disease.

Authors:  Po-Chao Hsu; Ho-Ming Su; Suh-Hang Juo; Hsueh-Wei Yen; Wen-Chol Voon; Wen-Ter Lai; Sheng-Hsiung Sheu; Tsung-Hsien Lin
Journal:  BMC Res Notes       Date:  2013-03-20

8.  Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: a cross-sectional study.

Authors:  Olga Kruszelnicka; Andrzej Surdacki; Alain Golay
Journal:  Cardiovasc Diabetol       Date:  2013-10-09       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.